Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US11027021B2 · kind B2 · utility
0Cited by
10References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2017 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Mar 15, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.